<DOC>
	<DOCNO>NCT00002977</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness melphalan thiotepa follow peripheral stem cell transplantation treat patient stage III stage IV epithelial ovarian cancer complete remission .</brief_summary>
	<brief_title>Melphalan Thiotepa Followed Peripheral Stem Cell Transplantation Treating Patients With Epithelial Ovarian Cancer Complete Remission</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxic effect combine high dose melphalan thiotepa chemotherapy follow stem cell rescue patient stage III IV ovarian epithelial cancer complete remission . II . Determine maximum tolerate dose thiotepa give melphalan patient . III . Evaluate interpatient blood level variability pharmacokinetics melphalan give intravenously . OUTLINE : This dose escalation study thiotepa . Patients receive cytoreduction mobilization peripheral blood stem cell ( PBSC ) filgrastim ( G-CSF ) cyclophosphamide/paclitaxel , cyclophosphamide/etoposide cyclophosphamide/etoposide/cisplatin within 30-90 day last dose standard therapy . PBSC collect . Patients receive melphalan IV 30 minute day -6 -5 thiotepa IV 2 hour day -4 -3 . PBSC reinfused day 0 . G-CSF administered day 0-21 . Cohorts 5-15 patient receive escalate dos thiotepa maximum tolerate dose ( MTD ) reach . The MTD determine dose 2-5 4-15 patient experience dose limit toxicity . Patients follow 100 day , 6 , 12 , 24 month . PROJECTED ACCRUAL : A total 30-45 patient accrue study 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III/IV ovarian epithelial cancer first second clinical complete remission receive minimum 410 course chemotherapy consist paclitaxel either cisplatin carboplatin Ovarian epithelial cancer follow histologic type : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Transitional cell Adenocarcinoma N.O.S . Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner 's Tumor Remission stability maintain least 4 week Protocol therapy must begin 3090 day last dose standard therapy No active pleural pericardial effusion No prior/concurrent brain metastasis carcinoid meningitis PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.0 time ULN Albumin great 2.0 g/dL Renal : Creatinine clearance great 60 mL/min Cardiovascular : Ejection fraction great 45 % MUGA Pulmonary : If history smoking abnormal lung function , Diffusion capacity great 50 % ( correct ) Aa gradient le 20 Other : No history hemorrhagic cystitis No second malignancy within last 5 year except basal cell skin cancer HIV negative No chronic active hepatitis B No hepatitis C No history Aspergillus infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior stem cell transplant Chemotherapy : Prior chemotherapy consist paclitaxel either cisplatin carboplatin Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy malignancy ( exclude chest wall radiation therapy breast cancer ) Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>